Immunotherapy and targeted Therapy combinations in renal Cancer

Current Clinical Pharmacology

Volumn 6, Issue 3, 2011, Pages 207-213

  McDermott, David F ^a  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

Immunotherapy; PD 1 blockade; Renal cell carcinoma

Indexed keywords

AGS 003; ALPHA INTERFERON; BEVACIZUMAB; FRESOLIMUMAB; HUMAN MONOCLONAL ANTIBODY; HYB 2055; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; MDX 1106; MEDROXYPROGESTERONE ACETATE; PROGRAMMED DEATH 1 LIGAND 1; SORAFENIB; SUNITINIB; THYROTROPIN; TRABEDERSEN; UNCLASSIFIED DRUG; URELUMAB;

ANOREXIA; ANTIANGIOGENIC THERAPY; ARTHRITIS; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHYSITIS; IMMUNOREGULATION; KIDNEY CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RASH; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052244000     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411797189451     Document Type: Article

References (56)

1. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338: 1265-1271.
2. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992; 148: 1247-1248.
3. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003; 21: 884-890.
4. Lesimple T, Moisan A, Guille F, et al. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factor. J Immun 2000; 23: 675-679.
5. Schwaab T, Heaney JA, Schned AR, et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 2000; 163: 1322-1327.
6. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
7. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169-1188.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
9. Motzer RJ, Hutson TE, Tomczak P, et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
10. Hudes G, Carducci M, Tomczak P, et al.Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
12. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696.
13. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl 1): S55-S57.
14. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-319.
15. Belldegrun A, Webb DE, Austin HA, 3rd, Steinberg SM, Linehan WM, Rosenberg SA. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol 1989; 141: 499-503.
16. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7: 486-498.
17. Neidhart JA. Interferon therapy for the treatment of renal cancer. Cancer 1986; 57: 1696-1699.
18. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987; 14: 36-42.
19. Muss HB, Costanzi JJ, Leavitt R, et al.Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987; 5: 286-291.
20. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil.Groupe francais d'immunotherapie, federation nationale des centres de lutte contre le cancer. J Clin Oncol 2000; 18: 4009-4015.
21. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical research council renal cancer collaborators. Lancet 1999; 353: 14-17.
22. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867.
23. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.
24. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-1278.
25. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132.
26. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141.
27. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110: 2468-2477.
28. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-3721.
29. McDermott. The high-dose Aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010; 28(15s): abstr 4514.
30. Yang JC, Haworth L, Sherry RM, et al.A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
31. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143.
32. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150.
33. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143.
34. Dandamudi.A, Phase II study of bevacizumab and high dose bolus aldesleukin (IL-2) in metastatic renal cell carcinoma patients: A Cytokine Working Group Study. J Clin Oncol 2010; 28(15s): abstr 5044.
35. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25: 3288-3295.
36. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-3301.
37. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-450.
38. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
39. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
40. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 1997; 7: 885-895.
41. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169-1177.
42. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-2970.
43. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4: 941-952.
44. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048.
45. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
46. Brahmer JR, Topalian S, Wollner I, et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2008; 26 (20 Suppl): abstr 3006).
47. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immun 2007; 30: 825-830.
48. Morris J, Shapiro G, Tan A, et al. Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGF) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008; 26(20 Suppl): abstr 9028).
49. Sznol M, Hodi F, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 2008; 26(20 Suppl): abstr 3007).
50. Schmidt H, Selby P, Mouritzen U, Thelin UH, Kristjansen PE, Geertsen P. Subcutaneous (SC) dosing of recombinant human interleukin-21 (rIL-21) is safe and has clinical activity: Results from a dose-escalation study in stage 4 melanoma (MM) or renal cell cancer (RCC). J Clin Oncol 2008; 26(20 Suppl): abstr 3041).
51. Moore DJ, Hwang J, McGreivy J, et al. Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. J Clin Oncol 2005 ASCO Annual Meeting Proceedings. 2005; 23(16S): 2503.
52. Amin A DA, Logan T. A phase II study testing the safety and activity of AGS-003 as an immunotherpeutic in subjets with newly diagnosed advanced stage renal cell carcinom in combination with sunitinib. J Clin Oncol 2010; 28: 4588.
53. Prieto. Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. J Clin Oncol 2010; 28(15s): abstr 8544.
54. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101: 17174-17179.
55. Sznol. Safety and antitumor activity of bi-weekly MDX1106 in patients with advanced or refractory malignancies. J Clin Oncol 2010; 28(15 Suppl): abstr 2506).
56. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70: 3526-5336.